Article Public (all visitors)

Science Corp raises $230M as it races to bring its brain implant to market | TechCrunch

TechCrunch 2026

A source close to the company says the round assigns Science a post-money valuation of $1.25 billion.

“Science Corp. is betting on PRIMA, a chip said to be smaller than a grain of rice that, when implanted in the eye, works with camera-equipped glasses to restore functional vision to people suffering from advanced macular degeneration.”

View Original Source

Curated by

FoundryBase

Updated about 2 months ago

Visibility Public (all visitors)

Saved in 2 chunks

Kind Article

BIOLOGY BIOTECH BRAIN COMPANIES

Response

Browse more

View All Articles

Summary:

Summary: Science Corp has successfully raised $230 million in funding, leading to a post-money valuation of $1.25 billion. The company is focused on advancing its product, PRIMA, a tiny chip designed to be implanted in the eye to assist individuals with advanced macular degeneration by working in conjunction with camera-equipped glasses to restore their vision.

Context Addition:

Advanced macular degeneration is a common cause of vision loss among older adults, affecting millions globally. The development of innovative technologies like PRIMA represents a significant step forward in the field of ocular implants and vision restoration, potentially offering new hope for patients who have limited treatment options. Science Corp's efforts align with broader trends in biotech where companies are increasingly exploring neurotechnology solutions for various sensory impairments.

Keywords: brain implant, vision restoration, macular degeneration, biotech innovation, ocular technology

No comments yet. Be the first to comment!